News from AIDS 2012

The 19th International AIDS Conference (AIDS 2012) took place in Washington, USA, 22nd-27th July 2012.

As the official online partner for scientific reporting, NAM published original news reporting and free email bulletins.

aidsmap news from AIDS 2012

Population viral load decreases in 'test and treat' study in Uganda

Positive changes in population-level HIV viral load distribution have been found one year after the implementation of key components of an HIV 'test-and-treat' strategy in rural Uganda. Population

Published
25 July 2012
By
Lesley Odendal
Studies highlight complex questions about how communities will respond to PrEP

Two consecutive sessions at the 19th International AIDS Conference (AIDS 2012) in Washington DC highlighted some of the complexities of translating exciting research findings about pre-exposure prophylaxis

Published
25 July 2012
By
Kelly Safreed-Harmon
Novel TB combination regimen shows potent activity in randomised short-term clinical trial

A new TB drug, PA-824, showed very potent early bactericidal activity in a randomised 14-day study in people with TB, when used in combination with the established antibiotic

Published
25 July 2012
By
Theo Smart
Once-daily maraviroc plus boosted atazanavir promising at 96 weeks

A NRTI-sparing regimen of maraviroc (Celsentri or Selzentry) plus ritonavir-boosted atazanavir (Reyataz) produced good virological suppression and was generally well tolerated through 96 weeks, according to

Published
25 July 2012
By
Liz Highleyman
The paradox of HIV in black MSM in the US – very high infection rates despite no more risky sex and more precautions

A new meta-analysis, presented to the 19th International AIDS Conference (AIDS 2012) on Tuesday, shows that the exceptionally high rates of HIV infection seen in black

Published
25 July 2012
By
Roger Pebody
International AIDS Conference hears how drugs, sex and HIV interlock

Two sessions at the 19th International AIDS Conference (AIDS 2012) in Washington looked at the way injecting drug use, recreational drug use and unsafe sex interlock to

Published
25 July 2012
By
Gus Cairns
Adolescent antiretroviral options expanding

A range of new antiretroviral drugs are in development for adolescents with HIV, a population which may have extensive experience of antiretroviral therapy and resistance to some

Published
25 July 2012
By
Carole Leach-Lemens
New antiretrovirals for infants and children still needed

Promising new formulations of antiretroviral agents including tenofovir, fosamprevanir, dolutegravir, etravirine and raltegravir for treating the often neglected needs of infants, children and adolescents with HIV were presented

Published
25 July 2012
By
Carole Leach-Lemens
Uganda field study finds that HIV treatment has not reduced new infections in couples

In an uncomfortable finding for advocates of treatment as prevention, a study of heterosexual couples of differing HIV status in Uganda has found no difference in the

Published
24 July 2012
By
Gus Cairns
Hillary Clinton pledges money for vulnerable minorities, reproductive rights, AIDS-free families

US Secretary of State Hillary Clinton received a relatively warm reception yesterday at the 19th International AIDS Conference (AIDS 2012) in Washington DC, as she supported the

Published
24 July 2012
By
Gus Cairns

Sign up today

Sign up for our regular email bulletins:

Find out more and sign up to the full range of aidsmap email bulletins >

AIDS 2012 tweets

Click here for more >

More coverage of the conference

Two other official partners of the conference are providing coverage and analysis online.

Clinical Care Options (CCO) provide audio highlights, capsule summaries and downloadable slidesets, while the Kaiser Family Foundation provide webcasting from conference sessions.

NAM is partnering with UNICEF to deliver the AIDS 2012 bulletins, which have also been made possible thanks to support from Bristol-Myers Squibb and Vestergaard Frandsen. NAM’s wider conference news reporting services have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and ViiV Healthcare.